What Ebglyss Treats
Ebglyss (lebrikizumab-lbkz) is an interleukin-13 (IL-13) inhibitor injection approved by the FDA for moderate-to-severe atopic dermatitis (eczema) in adults and children 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.[1]
How Ebglyss Works
It targets IL-13, a key protein driving inflammation in atopic dermatitis, reducing itch, skin inflammation, and barrier dysfunction.[1]
Who Can Use It
Eligible patients have atopic dermatitis covering at least 10% of body surface area, with a baseline Investigator's Global Assessment score of 3 or 4, and an Eczema Area and Severity Index score of 16 or higher.[1] It's not for mild cases or as first-line treatment.
Dosage and Administration
Administered as a subcutaneous injection. Loading dose: 500 mg (two 250 mg injections) at weeks 0, 2, and 4. Maintenance: 250 mg every 2 weeks. Can be self-administered after training.[1]
Common Side Effects
Herpes infections (6.9%), injection site reactions (2.7%), conjunctivitis (1.7%). Serious risks include hypersensitivity reactions and parasitic infections—avoid live vaccines.[1]
How It Compares to Dupixent
Both are IL-4/IL-13 blockers for eczema, but Ebglyss specifically inhibits IL-13. In trials, Ebglyss showed similar efficacy to Dupixent in itch reduction and clear/almost clear skin at week 16 (43% vs. 33% for Dupixent in one head-to-head study).[2]
When Did FDA Approve It?
September 15, 2024, based on ADvocate1 and ADvocate2 phase 3 trials with over 850 patients.[1]
Who Makes Ebglyss
Eli Lilly and Company.[1]
Patent and Pricing Details
U.S. patents extend to at least 2036; check DrugPatentWatch.com for expiration dates, challenges, and generics.[3] List price: ~$8,000-$10,000 per month before discounts or insurance.
[1] FDA Prescribing Information for Ebglyss (September 2024).
[2] NEJM: Lebrikizumab vs. Dupilumab (2023).
[3] DrugPatentWatch.com: Ebglyss patents.